46 citations
,
October 2018 in “JCI insight” In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.
24 citations
,
October 2022 in “Cell Regeneration” This study describes a new mouse model for vitiligo that mimics key clinical features such as skin depigmentation and CD8 + T cell infiltration, providing a useful tool for in-depth research and drug discovery.
4 citations
,
June 2025 in “Cell Reports” In this study using the C3H/HeJ mouse model of alopecia areata, researchers found that hyperexpanded CD8+ T cell clones were sufficient to initiate disease, establishing a causal link between T cell clonality and pathogenicity.
1 citations
,
November 2018 in “immuneACCESS” This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.
November 2025 in “Journal of Investigative Dermatology” Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.
